Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186953 · ClinicalTrials.gov registry record · Phase 1
Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00186953 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 14 participants.
The verdict
NCT00186953, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's Research Hospital researchers want to learn the best and safest dose of this ultrasound "dye."
Interventions
- DRUG Optison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186953
The ClinicalTrials.gov registry entry for NCT00186953 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optison is the first listed.
NCT00186953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186953 about?
NCT00186953 is a clinical study titled "Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors". St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are ...
What is the current status of trial NCT00186953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2002-06. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00186953?
The interventions under investigation include: Optison (DRUG).
Who is sponsoring clinical trial NCT00186953?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.